Eli Lilly and Co. turned to Finnegan, Henderson, Farabow, Garrett & Dunner to stop numerous generic drug makers from muscling into the multibillion-dollar market for depression and diabetes-related pain drug Cymbalta.
Clients like Eli Lilly “look to us for important cases about maintaining their exclusivity,” said Dori Hines, who leads the litigation practice at the Washington-based firm. After a March 2011 final judgment against the named defendant in Eli Lilly and Co. v. Wockhardt Ltd., the other eight defendants in the Southern District of Indiana case settled the next month. Finnegan has “a deep bench in terms of all of the technical areas” covered by IP litigation, Hines said.
